Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
108M
-
Number of holders
-
102
-
Total 13F shares, excl. options
-
28.5M
-
Shares change
-
+2.89M
-
Total reported value, excl. options
-
$735M
-
Value change
-
+$71.5M
-
Put/Call ratio
-
0.08
-
Number of buys
-
65
-
Number of sells
-
-36
-
Price
-
$25.81
Significant Holders of Aclaris Therapeutics, Inc. - Common Stock (ACRS) as of Q3 2017
116 filings reported holding ACRS - Aclaris Therapeutics, Inc. - Common Stock as of Q3 2017.
Aclaris Therapeutics, Inc. - Common Stock (ACRS) has 102 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 28.5M shares
of 108M outstanding shares and own 26.31% of the company stock.
Largest 10 shareholders include Vivo Capital, LLC (2.86M shares), FMR LLC (2.16M shares), FRANKLIN RESOURCES INC (2.03M shares), BlackRock Inc. (1.71M shares), DEERFIELD MANAGEMENT CO (1.58M shares), Sofinnova Management VIII, L.L.C. (1.54M shares), EAGLE ASSET MANAGEMENT INC (1.38M shares), Polar Capital LLP (1.35M shares), VANGUARD GROUP INC (1.18M shares), and WESTFIELD CAPITAL MANAGEMENT CO LP (1.09M shares).
This table shows the top 102 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.